Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials

LY3437943 · ClinicalTrials.gov · reviewed 2026-08-17

Retatrutide clinical trials, in English

Retatrutide is an investigational medicine on the registry. Listings here are studies, not an approved-use guide. Dose, indication, and eligibility are only on the NCT record. Search the same name on ClinicalTrials.gov.

Also tagged in this snapshot for: Metabolic Dysfunction-Associated Steatotic Liver Disease · Obesity

RecruitingPhase 3Tuscaloosa, Alabama
Phase 3: testing Tirzepatide for Metabolic Dysfunction-Associated Steatotic Liver Disease

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.

NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company

RecruitingPhase 2Shenzhen, Guangdong
Phase 2: testing Retatrutide (LY3437943) for Obesity

Phase 2, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus dummy treatment (placebo) in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

NCT07467447 · Official ClinicalTrials.gov record · Hudson Biotech

FAQ: Retatrutide studies

Are there recruiting Retatrutide clinical trials?

This snapshot currently includes 2 recruiting records that name Retatrutide (or an alias) as an intervention. Also searched as LY3437943. Confirm the intervention list on ClinicalTrials.gov; names can appear in combination studies.

Does a Retatrutide listing mean the drug is approved for that use?

No. ClinicalTrials.gov lists research studies. An NCT number is not prescribing information and is not an FDA approval for you.

Is PlainTrials affiliated with the maker of Retatrutide?

No. Brand and generic names are copied from public registry intervention fields so you can find the matching NCT record.

Other intervention hubs

Ozempic · Wegovy

Semaglutide

A GLP-1 weekly shot (and a daily pill) being tested far beyond diabetes — obesity, heart, kidney, liver, and addiction studies.

Mounjaro · Zepbound

Tirzepatide

A dual GIP/GLP-1 weekly shot. Trials now cover weight, sleep apnea, heart failure, and fatty liver.

Keytruda

Pembrolizumab

A PD-1 immunotherapy used across many cancers. New trials test earlier use, combinations, and shorter courses.

Opdivo

Nivolumab

A PD-1 immunotherapy studied alone and with ipilimumab or chemotherapy.

Enhertu · T-DXd

Trastuzumab deruxtecan

An HER2-directed antibody-drug conjugate studied in breast, lung, gastric, and other tumors.

Tagrisso

Osimertinib

An EGFR tyrosine-kinase inhibitor studied in lung cancer and related settings.